Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid ...

For decades, Americans struggling with pain had two options to find relief: over-the-counter medication such as ibuprofen, which often provided limited reprieve, or prescription opioids, and the ...

Vertex's Chronic Pain Ambitions Hit Roadblock with LSR Data So much of Journavx's potential lies in chronic pain management. In December, Vertex revealed Phase 2 data evaluating Journavx in ...

Evidence suggests that Journavx doesn't pose a risk of addiction as opioid medications do, making it a potentially safer alternative for pain management. "A new therapeutic class of non-opioid ...

The U.S. Food and Drug Administration (FDA) has approved Journavx, the first opioid-free prescription drug for moderate to ...

[Journavx] may help prevent the transition to chronic pain, reducing the need for long-term pain management strategies,” he said. Learn more about Journavx in the YouTube clip below.

The FDA approved the first drug in its class that targets moderate to severe acute pain in adults, without being addictive ...

“I believe JOURNAVX could redefine the management of pain and become a foundational treatment option for people with all types of moderate-to-severe acute pain, where options aside from opioids ...

For the first time in more than 25 years, the U.S. Food and Drug Administration has signed off on a new type of pain reliever ... have available," Davis said. Journavx is a drug newly approved ...

Journavx (suzetrigine), made by Vertex ... meeting a "major unmet need," noted Jianguo Cheng, MD, PhD, a pain management specialist at Cleveland Clinic. "This is the first time in nearly two ...